Skip to main content

Publications

Found 58 results
Author Title [ Year(Desc)]
Filters: First Letter Of Last Name is W  [Clear All Filters]
2011
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
Magee LA, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane J, et al.. Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529.  (298.54 KB)
Magee LA, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane J, et al.. Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529.  (298.54 KB)
Magee LA, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane J, et al.. Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529.  (298.54 KB)
Millman A, Payne BA, Qu Z, M Douglas J, Hutcheon J, Lee T, et al.. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714.  (383.37 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
Yen T-W, Payne BA, Qu Z, Hutcheon J, Lee T, Magee LA, et al.. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809.  (269.78 KB)
2016
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76.  (803.67 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159.  (476.19 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG. 2016;123(7):1135-41.  (144.71 KB)
Ahmed R, Gafni A, Hutton E, Hu Z, Pullenayegum E, von Dadelszen P, et al.. The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension. 2016;68(4):1049-55.  (470.91 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143-51.  (153.93 KB)
Burke O, Benton S, Szafranski P, von Dadelszen P, S Buhimschi C, Cetin I, et al.. Extending the scope of pooled analyses of individual patient biomarker data from heterogeneous laboratory platforms and cohorts using merging algorithms. Pregnancy Hypertens. 2016;6(1):53-9.  (821.08 KB)
Staff A, Redman C, Williams D, Leeson P, Moe K, Thilaganathan B, et al.. Pregnancy and Long-Term Maternal Cardiovascular Health: Progress Through Harmonization of Research Cohorts and Biobanks. Hypertension. 2016;67(2):251-60.  (854.88 KB)
Duffy J, Hooft Jvan 't, Gale C, Brown M, Grobman W, Fitzpatrick R, et al.. A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens. 2016;6(4):274-278.  (336.66 KB)
Duffy J, Hooft Jvan 't, Gale C, Brown M, Grobman W, Fitzpatrick R, et al.. A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens. 2016;6(4):274-278.  (336.66 KB)
Ryan H, Sharma S, Magee LA, Ansermino JM, MacDonell K, Payne BA, et al.. The Usefulness of the APACHE II Score in Obstetric Critical Care: A Structured Review. J Obstet Gynaecol Can. 2016;38(10):909-918.  (304.95 KB)
Vidler M, Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, et al.. Women's views and postpartum follow-up in the CHIPS Trial (Control of Hypertension in Pregnancy Study). Eur J Obstet Gynecol Reprod Biol. 2016;206:105-113.  (412.73 KB)

Pages